JZP3507 Clinical Trials (2026): 1 Studies for Meningioma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 JZP3507 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Meningioma) and 30 total planned enrollment. 1 JZP3507 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07533942 (Oct 2031).
Where to Participate: All JZP3507 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting JZP3507trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| NY | NYU- Langone Health | New York10016 | NCT07533942 | Map |
JZP3507 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting JZP3507 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07533942 | ONC206A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | P2 | Meningioma | 30 | Jul 2026 |
JZP3507 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ONC206 | NCT07533942 | P2 | recruiting | Meningioma | 30 | — |
All JZP3507 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07533942 | ONC206 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | P2 | recruiting | 30 | Jazz Pharmaceuticals | Jul 2026 |
JZP3507 clinical trials: frequently asked questions
- How many JZP3507 clinical trials are there?
- 1 JZP3507 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are JZP3507 clinical trials recruiting in 2026?
- Yes — 1 JZP3507 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is JZP3507 being studied for?
- JZP3507 is being studied for Meningioma. The trials are grouped by indication on this page.
- What phase is JZP3507 in?
- JZP3507 clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors JZP3507 clinical trials?
- The lead sponsor across the most JZP3507 trials is Jazz Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming JZP3507as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: